Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Plecanatide
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Salix Will Share TRULANCE (Plecanatide) Data At The 2021 AANP National Conference
Details : TRULANCE® (plecanatide) is a guanylate cyclase-C (GC-C) agonist, indicated in adults for the treatment of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C).
Product Name : Trulance
Product Type : Peptide
Upfront Cash : Inapplicable
June 15, 2021
Lead Product(s) : Plecanatide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plecanatide
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Poster titled "The Impact of Plecanatide on Abdominal Pain in Patients with Chronic Idiopathic Constipation and Irritable Bowel Syndrome with Constipation: Analysis from Four Phase 3 Studies" at the The American College Of Gastroenterology 2020 Virtual A...
Product Name : Trulance
Product Type : Peptide
Upfront Cash : Inapplicable
October 22, 2020
Lead Product(s) : Plecanatide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable